Open Access Open Access  Restricted Access Subscription Access

An Emerging Respiratory Infection and its Associated Multiple Disabilities with Preparedness against Coronavirus

Dr. Prashant Tiwari, Dr. Shweta Shrivastava, Priyadarshini Biswal


Recently coronavirus (COVID-19) associated, life-threatening comorbidities became vital challenges worldwide. It is anticipated that about 210 countries and territories around the world are being affected by COVID-19. Coronavirus mainly causes Severe Acute Respiratory Syndrome (SARS). In addition, to Middle East Respiratory Syndrome (MERS) is a severe, acute respiratory illness caused by the MERS coronavirus (MERS-COVID-19). Coronavirus was also accountable for multiple disabilities such as asthma, chronic pulmonary obstructive disease (COPD) and diabetes. At present, there is no vaccination available to moderate the COVID-19. However, social distancing, self-isolation, and quarantine is a protective tool. In this connection, there are as such no drug treatment/therapy available to modulate the coronavirus. Still, there are few antiviral drugs are being prescribed to diminish the coronavirus infection such as Ribavirin along with Corticosteroids may be given to patients with critical disease (admitted in ICU). These drugs may also be given to SARS associated adversity. Aside from that Hydroxychloroquine and Remdesivir may be given to COVID patients because these drugs inhibit virus infection at the micromolar level.  In addition to that following observations may also be taken care such as to reassure and counsel patients, advise droplet precautions, observe closely for conditions, high-risk cases shall be considered for admission based on clinical judgment and repeat the temperature monitoring, blood pressure check-up every day.. Considering the above mentioned it is proposed to all of us unless and until we don’t have any specified drug of choice to counter coronavirus, we must accompany the guidelines published by WHO and AYUSH.

Full Text:



M.L. Barreto, M.G. Teixeira, E.H. (2006), “Infectious diseases epidemiology”, J. Epidemiol. Community Health, Volume 60, Issue 3, pp. 192-195, DOI:

Tai DY. (2007), “Pharmacologic treatment of SARS: Current knowledge and recommendations”, Ann Acad Med Singapore, Volume 36, pp. 438-443, Available at:

Andera G. et al, (1999), “Neuraminidase inhibitors for treatment of influenza A and B infections”, MMWR Recomm. Rep., Volume 48, pp. 1-9.

Bleibtreu A, Jaureguiberry S, Houhou N, Boutolleau D, Guillot H, Vallois D, et al. (2018), “Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016”, BMC Infect. Dis., Volume 18, pp. 331, Available at:

Al-Abdely HM, Midgley CM, Alkhamis AM, Abedi GR, Lu X, Binder AM, et al. (2019), “Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients”, Saudi Arabia. Emerg. Infect. Dis., Volume 25, pp. 753-766, DOI:

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020), “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”, Lancet, Volume 395, pp. 497-506, DOI:

Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. (2020), “Reducing mortality from 2019-nCoV: Host-directed therapies should be an option, Lancet, Volume 395, pp. e35-6, DOI:

World Health Organization (13 March 2020), “Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection is Suspected” Available from:

Russell CD, Millar JE, Baillie JK. (2020), “Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury”, Lancet, Volume 395, pp. 473-475, DOI:

Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. (2003), “Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China”, J. Med. Microbiol., Volume 52, pp. 715-20, DOI:

Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. (2003), “Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: A preliminary study”, JAMA, Volume 290, pp. 3222-3228, DOI:

Lau AC, Yam LY, So LK. (2004), “Management of critically Ill patients with severe acute respiratory syndrome (SARS)”, Int. J. Med. Sci., Volume 1, Issue 1, pp. 1-10, Available at:

Tsang K, Zhong NS. (2003), “SARS: Pharmacotherapy”, Respirology, Volume 8, Issue S1, pp. S25-30. DOI:

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. (2004), ‘Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings”, Thorax, Volume 59, pp. 252-256, DOI:

Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. (2020), “A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)”, Mil. Med. Res. Volume 7, Article no. 4, DOI:

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (2020), “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”, Cell Res., Volume 30, pp. 269-271, DOI:

Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. (2016), “Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys”, Nature, Volume 531, pp. 381-385, DOI:

World Health Organization (28 January 2020), “Novel Coronavirus (2019-nCoV)”, Available from:

World Health Organization (13 March 2020), “Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected”, Available from:

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. (2005), “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”, Virol. J., Volume 2, Article id: 69, DOI:


  • There are currently no refbacks.